HQGG also acted on various signaling pathways to treat MAFLD, such as the AGE‐RAGE signaling pathway in diabetic complications, lipid and atherosclerosis, non‐alcoholic fatty liver disease, and the IL‐17 signaling pathway. This evidence concerns the gene IL17A and atherosclerosis.